Business Context and Reporting Period
Company: GSK Plc
Filing Type: Form 6-K (Results Announcement)
Reporting Period: Full Year 2021 and Fourth Quarter 2021
Issued Date: February 9, 2022
GSK reported full-year 2021 results, highlighting strong commercial execution across Pharmaceuticals, Vaccines, and Consumer Healthcare. The company is on track to demerge its Consumer Healthcare business in mid-2022 to create a new world-leading consumer health company. The results include significant contributions from COVID-19 solutions, specifically the monoclonal antibody Xevudy and pandemic adjuvant sales.
Key Financial Metrics
| Metric | Full Year 2021 | Q4 2021 |
|---|---|---|
| Turnover | £34.1 billion (Stable AER, +5% CER) | £9.5 billion (+9% AER, +13% CER) |
| Total Operating Profit | £6.2 billion (-20% AER, -9% CER) | £0.9 billion (-16% AER, +1% CER) |
| Adjusted Operating Profit | £8.8 billion (-1% AER, +9% CER) | £1.9 billion (+4% AER, +15% CER) |
| Total EPS | 87.6p (-24% AER, -13% CER) | 15.0p (+10% AER, +31% CER) |
| Adjusted EPS | 113.2p (-2% AER, +9% CER) | 25.6p (+9% AER, +22% CER) |
| Net Cash from Operations | £8.0 billion | £3.8 billion |
| Free Cash Flow | £4.4 billion | £2.9 billion |
| Net Debt | £19.8 billion (as of Dec 31, 2021) | N/A |
Material Changes vs. Prior Period
- Pharmaceuticals: Turnover grew 4% AER (+10% CER) to £17.7 billion. Growth was driven by New and Specialty medicines (+20% AER), particularly Respiratory (+21% AER), Immuno-inflammation (+22% AER), and Oncology (+31% AER). COVID-19 solution Xevudy contributed £958 million in sales.
- Vaccines: Turnover declined 3% AER (+2% CER) to £6.8 billion. Shingrix sales fell 13% AER due to pandemic-related disruptions in routine adult vaccination, partially offset by pandemic adjuvant sales of £447 million.
- Consumer Healthcare: Turnover decreased 4% AER (stable CER) to £9.6 billion. Excluding divested brands, sales grew 4% CER, driven by e-commerce and underlying brand strength.
- Profitability: Total operating profit declined primarily due to an unfavorable comparison with the 2020 net profit on the disposal of Horlicks and other Consumer brands. Adjusted operating profit increased 9% CER, supported by pandemic sales and cost discipline.
- Legal Settlement: A post-balance sheet event on February 1, 2022, saw ViiV Healthcare settle patent litigation with Gilead, resulting in a $1.25 billion upfront payment and future royalties. This settlement increased the fair value of contingent consideration liabilities recorded in 2021 results.
Guidance, Outlook, and Risks
2022 Guidance for New GSK (Biopharma):
- Sales Growth: 5% to 7% at Constant Exchange Rate (CER).
- Adjusted Operating Profit Growth: 12% to 14% at CER.
- Exclusions: Guidance excludes the commercial impact of COVID-19 solutions.
Management Commentary:
CEO Emma Walmsley described 2022 as a "landmark year" with a step-change in growth expected, driven by R&D catalysts and the demerger of Consumer Healthcare. The company expects milestones on up to 7 key late-stage pipeline assets in 2022.
Risks and Contingencies:
- COVID-19 Impact: Continued disruption to adult immunizations is expected in the first half of 2022 due to government prioritization of COVID-19 vaccination programs.
- Generic Competition: Increased genericization of established Respiratory products is expected to slightly decrease General Medicines sales.
- Legal and Tax: The company faces ongoing legal proceedings and tax disputes; ultimate liabilities may vary from provisions.
- Demerger Execution: The separation of Consumer Healthcare is targeted for mid-2022, subject to regulatory approvals.
Investor Verification Checklist
- Adjusted vs. Total Results: Verify the reconciliation between Total and Adjusted results, noting significant adjusting items such as contingent consideration re-measurements (£1.1 billion charge in 2021) and restructuring costs.
- COVID-19 Sustainability: Assess the sustainability of Xevudy and pandemic adjuvant sales, which contributed approximately 4 percentage points to full-year turnover growth but are excluded from 2022 guidance.
- Consumer Healthcare Demerger: Monitor progress on the mid-2022 demerger and the separate Capital Markets Day scheduled for February 28, 2022, for detailed financials on the new Consumer Healthcare entity.
- Gilead Settlement Impact: Confirm the timing of the $1.25 billion upfront payment from Gilead (expected Q1 2022) and the recognition of future royalty income.
- Contingent Consideration Liability: Review the sensitivity of the ViiV Healthcare contingent consideration liability (£5.6 billion) to sales forecasts and exchange rates.